Dhurandhar Vikrant, Bhola Nalini, Chan Mico, Choi Sarah, Chung Tzu-Yun, Giuffre Bruno, Hunter Nigel, Lee Katelyn, McKessar Merran, Reddy Ranjani, Roberts Marian, Shearman Christine, Kay Meredith, Bruderlin Ken, Winarta Niko, Noakes Jennifer
Department of Radiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Northern Sydney & Central Coast BreastScreen, Sydney, New South Wales, Australia.
J Med Imaging Radiat Oncol. 2024 Jun;68(4):401-411. doi: 10.1111/1754-9485.13664. Epub 2024 May 2.
While digital breast tomosynthesis (DBT) has proven to enhance cancer detection and reduce recall rates (RR), its integration into BreastScreen Australia for screening has been limited, in part due to perceived cost implications. This study aims to assess the cost effectiveness of digital mammography (DM) compared with synthesized mammography and DBT (SM + DBT) in a first round screening context for short-term outcomes.
Clients recalled for nonspecific density (NSD) as a single lesion by both readers at the Northern Sydney Central Coast BreastScreen service in 2019 were included. Prior images were excluded to simulate first-round screening. Eleven radiologists read DM and synthesized mammography with DBT (SM + DBT) images 4 weeks apart. Recall rates (RR), reading time, and diagnostic parameters were measured, and costs for screen reading and assessment were calculated.
Among 65 clients studied, 13 were diagnosed with cancer, with concordant cancer recalls. SM + DBT reduced recall rates (RR), increased reading time, maintained cancer detection sensitivity, and significantly improved other diagnostic parameters, particularly false positive rates. Benign biopsy recalls remained equivalent. While SM + DBT screen reading cost was significantly higher than DM (DM AU$890 ± 186 vs SM + DBT AU$1279 ± 265; P < 0.001), the assessment cost (DM AU$29,504 ± 9427 vs SM + DBT AU$18,021 ± 5606; P < 0.001), and combined screen reading and assessment costs were significantly lower (DM AU$30,394 ± 9508 vs SM + DBT AU$19,300 ± 5721; P = 0.001). SM + DBT screen reading and assessment of 65 patients resulted in noteworthy cost savings (AU$11,094), equivalent to assessing 12 additional clients.
In first round screening, DBT yields significant cost savings by effectively reducing unnecessary recalls to assessment while maintaining diagnostic efficacy.
虽然数字乳腺断层合成(DBT)已被证明可提高癌症检测率并降低召回率(RR),但其在澳大利亚乳腺筛查项目中的应用有限,部分原因是人们认为其成本较高。本研究旨在评估在首轮筛查中,数字乳腺钼靶(DM)与合成乳腺钼靶及数字乳腺断层合成(SM + DBT)相比,在短期结果方面的成本效益。
纳入2019年在悉尼北部中央海岸乳腺筛查服务中心被两位阅片者均因非特异性密度(NSD)作为单一病变而召回的客户。排除先前的影像以模拟首轮筛查。11位放射科医生在相隔4周的时间里阅读DM以及合成乳腺钼靶与数字乳腺断层合成(SM + DBT)的影像。测量召回率(RR)、阅片时间和诊断参数,并计算筛查阅片和评估的成本。
在研究的65位客户中,13位被诊断患有癌症,癌症召回结果一致。SM + DBT降低了召回率(RR),增加了阅片时间,保持了癌症检测的敏感性,并显著改善了其他诊断参数,尤其是假阳性率。良性活检召回率保持不变。虽然SM + DBT的筛查阅片成本显著高于DM(DM为890澳元±186,SM + DBT为1279澳元±265;P < 0.001),但评估成本(DM为29,504澳元±9427,SM + DBT为18,021澳元±5606;P < 0.001)以及筛查阅片和评估的综合成本显著更低(DM为30,394澳元±9508,SM + DBT为19,300澳元±5721;P = 0.001)。对65例患者进行SM + DBT筛查阅片和评估可显著节省成本(11,094澳元),相当于可额外评估12位客户。
在首轮筛查中,数字乳腺断层合成通过有效减少不必要的评估召回同时保持诊断效能,从而显著节省成本。